On the growth rates of human malignant tumors: Implications for medical decision making

Nowotwory

Volumn 55, Issue 1, 2005, Pages 1-22

  Friberg, Sten ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE   (Sweden)

Author keywords

Diagnostic level; Doubling time; Growth rate; Human; Lethal burden; Neoplasm; Period of risk

Indexed keywords

ADULT; AGED; BREAST CANCER; CANCER GROWTH; CANCER SCREENING; CANCER SURVIVAL; CELL KINETICS; CELL POPULATION; CELL PROLIFERATION; CHILDHOOD CANCER; COLON CANCER; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; EXPOSURE; FEMALE; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; MESENCHYMOMA; METASTASIS; PROGNOSIS; PROSTATE CANCER; REVIEW; RISK ASSESSMENT; TESTIS CARCINOMA; TUMOR CELL; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 15944412161     PISSN: 0029540X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (135)

1. Friberg S, Mattson S. On the growth rates of human malignant tumors: Implications for medical decision making. J Surg Oncol 1997; 65: 284-97.
2. Holmgren L, O'Reilly M, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1995; 1: 149-53.
3. Virchow R. "Vorlesungen über Pathologie". Berlin: A Hirchwald Verlag, 1862, p 1.
4. Waldenström J. Hypergammaglobulinemia as a clinical hematologic problem: A study in the gammopathies. Progr Haemotol 1962; 3: 266-93.
5. Fialkow PJ. The origin and development of human tumors studied with cell markers. N Engl J Med 1974; 291: 26-34.
6. Hobbs JR. Growth rates and responses to treatment in human myelomatosis. Brit J Haemat 1969; 16: 607-17.
7. Hobbs J. Immunocytoma o' mice an' men. Br Med J 1971; 2: 67-72.
8. Gilliland DG, Blanchard KL, Levy J et al. Clonality in myeloproliferative disorders: Analysis by means of the polymerase chain reaction. Proc Natl Acad Sci USA 1991; 88: 6848-52.
9. Sidransky DS, Frost P, von Eschenbach A et al. Clonal origin of bladder cancer. N Engl J Med 1991; 326: 737-40.
10. Noguchi S, Aihara T, Koyama H et al. Discrimination between multicentric and multifocal carcinomas of the breast through clonal analysis. Cancer 1994; 74: 872-77.
11. Wang N, Perkins KL, Bronson DL et al. Cytogenetic evidence for premeiotic transformation of human testicular cancers. Cancer Res 1981; 41: 2135-40.
12. Skakkebaekk NE, Berthelsen JU, Giwercman A et al. Carcinoma-in-situ of the testis: possible origin from gonocytes and precursors of all types of germ cell tumors except spermatocytoma. Int J Urol Androl 1987; 10: 19-28.
13. Chaganti RSK, Rodriguez E, Mathew S. Origin of adult male mediastinal germ-cell tumors. Lancet 1994; 343: 1130-2.
14. Steel GG. Cell loss as a factor in the growth rate of human tumours. Eur J Cancer 1967; 3: 381-7.
15. Refsum SB, Berdal P. Cell loss in malignant tumours in man. (Letter to Editor). Eur J Cancer 1967; 3: 235-236.
16. Collins VP, Loeffler RK, Tivey H: Observations on growth rates of human tumors. Am J Roentgen 1956; 76: 988-1000.
17. Schwartz M. A biomathematical approach Io clinical tumor growth. Cancer 1961; 14: 1271-94.
18. Spratt JS, Ter-Pogossian M, Long RTL. The detection and growth of intrathoracic neoplasms. Arch Surg 1963; 86: 283-8.
19. Garland LH, Coulson W, Wollin E. The rate of growth and apparent duration of untreated primary bronchial carcinoma. Cancer 1963; 16: 694-707.
20. Spratt JS, Spjut HJ, Roper CL. The frequency distribution of the rates of growth and the estimated duration of primary pulmonary carcinomas. Cancer 1963; 16: 687-93.
21. Spratt JS, Spratt TL: Rates of growth of pulmonary metastases and host survival. Ann Surg 1964; 159: 161-71.
22. Weiss W, Boucot KR, Cooper DA. Growth rate in the detection and prognosis of bronchogenic carcinoma. JAMA 1966; 198: 108-14.
23. Breur K. Growth rate and radiosensitivity of human tumors - I. Eur J Cancer 1966; 2: 157-71.
24. Breur K. Growth rate and radiosensitivity of human tumors - II. Eur J Cancer 1966; 2: 173-188.
25. Brenner MW, Holsti LR, Perttala Y. The study by graphical analysis of the growth of human tumours and metastases of the lung. Br J Cancer 1967; 21: 1-13.
26. Rambert PE, Malaise E, Laugier A et al. Donnés sur la vitesse de croissance de tumours humaines. Bulletin du Cancer 1968; 55: 323-42.
27. Meyer JA. The concept and significance of growth rates in human pulmonary tumors.Am Thorac Surg 1972; 14: 309-22.
28. Steele JD, Buell P. Asymptomatic solitary pulmonary nodules. Host survival, tumor size and growth rate. J Thorac Cardiovasc Surg 1973; 65: 140-51.
29. Pearlman AW. Growth rate investigation and tumor lethal dose in Ewing's sarcoma. Acta Radiol 1973; 12: 57-70.
30. Pearlman AW. Breast cancer: Influence of growth rate on prognosis and treatment evaluation. Cancer 1976; 38: 1826-33.
31. Pearlman AW. Fibrosarcaoma: The biomathematical approach to late metastases - a case report. Mount Sinai J Med 1979; 46: 255-60.
32. Pollock WF, Hastings N, Snyder WH. The Collins "period of risk" formula for malignant tumors in children, with particular reference to Wilms' tumor and neuroblastoma. Surgery 1960; 48: 606-9.
33. Fournier D v, Weber E, Hoeffken W et al. Growth rate of 147 mammary carcinomas. Cancer 1980; 45: 2198-207.
34. Rööser B, Petterson H, Alvegård T. Growth rate of pulmonary metastases from soft tissue sarcoma. Acta Oncol 1987; 26: 189-92.
35. Blomqvist C, Wiklund T, Tarkkanen M et al. Measurement of growth rate of lung metastases in 21 patients with bone or soft-tissue sarcoma. Brit J Cancer 1993; 68: 414-7.
36. Gompertz B. On the nature of the function expressive of the law of human mortality, and on a new mode of determining the value of life contingencies. Phil Trans Roy Soc London 1825; 115: 513-83.
37. Winsor CP. The Gompertz curve as a growth curve. Proc Nat Acad Sci 1932; 18: 1-8.
38. Steel GG, Lamerton LF. The growth rate of human tumours. Br J Cancer 1966; 20: 74-86.
39. Dethlefsen LA, Prewitt JMS, Mendelsohn ML. Analysis of tumor growth curves. J Natl Cancer Inst 1968; 40: 389-405.
40. Steel GG. Growth Kinetics of Tumours: Cell Population Kinetics in Relation to the Growth and Treatment of Cancer. Oxford: Clarendon Press; 1977.
41. Plevritis SK. A mathematical algorithm that computes breast cancer sizes and doubling times detected by screening. Mathematical Biosciences 2001; 171: 155-78.
42. van Leeuwen IMM, Zonneveld C, Kooijman SALM. The embedded tumour: host physiology is important for the evaluation of tumour growth. Brit J Cancer 2003; 89: 2254-63.
43. Kopans PB, Rafferty E, Georgian-Smith D et al. A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena. Cancer 2003; 97: 2951-9.
44. Stamey TA, Kabalin JN, McNEal JE et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076-83.
45. Spratt JS, Greenberg RA, Heuser LS. Geometry, growth rates and duration of cancer and carcinoma in situ of the breast before detection by screening. Cancer Res 1986; 46: 970-4.
46. Yankelevitz DF, Kostis WJ, Hensche CI et al. Overdiagnosis in chest radiographic screening for lung carcinoma - Frequency. Cancer 2003; 97: 1271-5.
47. Shackney SE, McCormack GW, Cuchural GJ. Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Int Med 1978; 89: 107-21.
48. Frei E, Freireich EJ. Progress and perspectives in the chemotherapy of acute leukaemia. Adv Chemother 1965; 2: 269-98.
49. Demicheli R. Growth of testicular neoplasm lung metastases: Tumor-specific relation between two Gompertzian parameters. Eur J Cancer 1980; 16: 1603-8.
50. Spratt JS, Ackerman LV. The growth of a colonic adenocarcinoma. Am Surg 1961; 27: 23-8.
51. Fujimoto N, Sugita A, Terasawa Y et al. Observations on the growth rate of renal cell carcinoma. Int J Urol 1995; 2: 71-6.
52. Kusama S, Spratt JS, Donegan WL et al. The gross rates of growth of human mammary carcinoma. Cancer 1972; 30: 594-9.
53. Peer P, van Dijk J, Hendriks J et al. Age-dependent growth rate of primary breast cancer. Cancer 1993; 71: 3547-51.
54. Kuroishi T, Tominaga S, Morimoto T et al. Tumor growth rate and prognosis of breast cancer mainly by mass screening. Jpn J Cancer Res 1990; 81: 454-62.
55. Amerlöv C, Emdin SO, Lundgren B et al. Breast carcinoma growth rate described by mammographic doubling time and S-phase fraction. Cancer 1992; 70: 1928-34.
56. Ingleby H, Moore L, Gershon-Cohen J. A roentgenographic study of the growth rate of 6 "early" cancers of the breast. Cancer 1958; 11: 726-30.
57. Ingleby H, Gershon-Cohen J. Comparative Anatomy, Pathology and Roentgenology of the Breast. Philadelphia: University of Pennsylvania Press; 1960.
58. Gershon-Cohen J, Berger SM, Klickstein HS. Roentgenography of breast cancer moderating concept of "biologic predeterminism". Cancer 1963; 16: 961-4.
59. Spratt JS, Kaltenbach ML, Spratt J. Cytokinetic definition of acute and chronic breast cancer. Cancer Res 1977; 37: 226-30.
60. Lundgren B. Observations on growth rate of breast carcinomas and its possible implications for lead time. Cancer 1977; 40: 1722-5.
61. Heuser L, Spratt JS, Polk HC. Growth rates of primary breast cancers. Cancer 1979; 43: 1888-94.
62. Heuser L, Spratt JS, Polk HC et al. Relation between mammary cancer growth kinetics and the interval between screenings. Cancer 1979; 43: 857-62.
63. Spratt JS, Chang AFC, Heuser LS et al. Acute carcinoma of the breast. Surg Gynecol Obstet 1983; 157: 220-2.
64. Buchanan JB, Spratt JS, Heuser LS. Tumor growth, doubling times and the inability of the radiobiologist to diagnose certain cancers. Radiol Clin N Am 1983; 21: 115-26.
65. Heuser LS, Spratt JS, Kuhns JG et al. The association of pathologic and mammographic characteristics of primary human breast cancers with "slow" and "fast" growth rates and with axillary lymph node metastases. Cancer 1984; 53: 96-98.
66. Spratt JS, Spratt JA. What is breast cancer doing before we can detect it? J Surg Oncol 1985; 30: 156-60.
67. Galante E, Guzzon A, Gallus G, et al. Prognostic significance of the growth rate of breast cancer: preliminary evaluation on the follow-up of 196 breast cancers. Tumori 1981; 67: 333-340.
68. Geddes DM. The natural history of lung cancer: a review based on rates of tumour growth. Br J Chest Dis 1979; 73: 1-17.
69. Weiss W. Tumor doubling time and survival of men with bronchogenic carcinoma. Chest 1974; 65: 3-8.
70. Charbit A, Malaise EP, Tubiana M. Relation between the pathological nature and growth rate of human tumors. Eur J Cancer 1971; 7: 307-15.
71. Chahinian P, Israel L. Survival gain and volume gain: Mathematical tools in evaluating treatments. Eur J Cancer 1969; 5: 625-9.
72. Mattson K, Holsti LR. Prognostic value of doubling time in lung cancer. Strahlentherapie 1980; 156: 632-6.
73. Brigham BA, Bunn PA, Minna JD et al. Growth rates of small cell bronchogenic carcinomas. Cancer 1978; 42: 2880-6.
74. Hasegawa M, Sone S, Takashima S et al. Growth rate of small lung cancers detected on mass CT screening. Brit J Radiol 2000; 73: 1252-9.
75. Winer-Muram H, Jennings SG, Tarver RD et al. Volumetric growth rate of stage I lung cancer prior to treatment: Serial CT scanning. Radiology 2003; 223: 798-805.
76. McLean IW, Foster WD, Zimmerman LE et al. Inferred natural history of uveal melanoma. Invest Ophthalmol Vis Sci 1980; 19: 760-70.
77. Gass, JDM. Comparison of uveal melanoma growth rates with mitotic index and mortality. Arch Ophtalmol 1985; 103: 924-31.
78. Manschet WA and van Strik R. Uveal melanoma: Therapeutic consequences of doubling times and irradiation results; a review. International Ophtalmology 1992; 16: 91-9.
79. Ollila DW, Stern SL, Morton DL. Tumor doubling time: A selection factor for pulmonary resection metastatic melanoma. J Surg Oncol 1998; 69: 206-11.
80. Eskelin S, Pyrhönen S, Summanen P et al. Tumor doubling times in metastatic malignant melanoma of the uvea. Ophtalmology 2000; 107: 1443-9.
81. Augsburger JJ, Gonder JR, Amsel J et al. Growth rates and doubling times of posterior uveal melanomas. Ophthalmology 1984; 91: 1709-15.
82. Umeda M, Nishimatsu N, Masago H et al. Tumor-doubling time and onset of pulmonary metastasis from adenoid carcinoma of the salivary gland. Oral Surg Oral Med Oral Pathol Radiol Endod 1999; 88: 473-8.
83. El-Serag HB and Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
84. Kubota K et al. Growth rate of primary single hepatocellular carcinoma. Determining optimal screening interval with contrast enhanced computed tomography. Digestive Diseases and Sciences 2003; 48: 581-6.
85. Okazaki N et al. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer 1989; 63: 2207-10.
86. Sheu JC et al. Growth rate of asymptomatic hepatocellular carcinoma and clinical implications. Gastroenterology 1985; 89: 259-66.
87. Knutson CO et al. Melanoma. Review. Curr Probl Surg 1971; 12: 3-55.
88. Schötterl H-D and Paul E. Growth dynamics of malignant melanoma. Tumor duplication time morphometrically measured in X-ray pictures of pulmonary metastases. Zeitschrift für Hautkrankenheiten 1988; 63: 481-7.
89. Plesnicar S, Klanjscek G, Modic S: Actual doubling time values of pulmonary metastases from malignant melanoma. Aust N Z J Surg 1978; 84: 23-5.
90. Combes PF, Douchez J, Carton M et al. Etude de la croissance des métastases pulmonaires humaines comme argument objectif d'evaluation du prognostic et des effets thérapiques. J Radiologie et d'Electrologie 1968; 49: 893-902.
91. Band PR, Kocandrle C. Growth rate of pulmonary metastases in human sarcomas. Cancer 1975; 36: 471-4.
92. Joseph WL, Morton DL, Adkins PC. Prognostic significance of tumor doubling time in evaluating operability in pulmonary metastatic disease. J Thor Cardiovasc Surg 1971; 61: 23-32.
93. Spratt JS. The rates of growth of skeletal sarcomas. Cancer 1965; 18: 14-24.
94. MacDonald JS. Radiological methods of measurement. In: Clinical Evaluation of Breast Cancer. New York: Hayward & Bulbrock; 1966, 11-34.
95. Tubiana M, Chauvel P, Renaud A et al. Vitesse de croissance et histoire naturelle du cancer du sein. Bulletin du Cancer 1975; 62: 341-58.
96. von Fournier D, Hoeffken W, Junkermann H et al. Growth rate of primary mammary carcinoma and its metastases. In: Zander J, BaltzerJ (eds). Early Breast Cancer. Berlin: Springer-Verlag; 1985.
97. Davies JNP Overview of the biology and pathology of metastasis. In: Day SB, Myers WPL, Stansly P et al (ed), Cancer Invasion and Metastasis: Biologic Mechanisms and Therapy: Progress in Cancer Research and Therapy. New York: Raven Press; 1977; 5: 15.
98. Bauer W, Igot JP, Le Gal Y. Chronologie du cancer mammaire utilisant un modèle de croissance de Gompertz. Annales d'Anatomie Patologique 1980; 25: 39-56.
99. Collins VP. The treatment of Wilms's tumor. Cancer 1958; 11: 89-94.
100. Knox WE, Pillers EMK. Time of recurrence or cure of tumours in childhood. Lancet 1958; 188-91.
101. Austin EJ, Alvord EC. Recurrences of cerebellar astrocytomas: A violation of Collins' law. J Neurosurg 1988; 68: 41-7.
102. Brown WD, Tavaré CJ, Sobel EL et al. Medulloblastoma and Collins' law: A critical review of the concept of a period of risk for tumor recurrence and patient survival. Neurosurgery 1995; 36: 691-7.
103. Allan E. Breast cancer: The long latent interval. Eur J Cancer 1977; 13: 839-45.
104. Duncan W, Kerr GR. The curability of breast cancer. Br Med J 1976; 2: 781-3.
105. Rutqvist LE, Wallgren A, Nilsson B. Is breast cancer a curable disease? Cancer 1984; 53: 1793-800.
106. Rutqvist LE, Wallgren A. Long-term survival of 458 young breast cancer patients. Cancer 1985; 55: 658-65.
107. Joensuu H, Toikkanen S. Cured of breast cancer? J Clin Oncol 1995; 13: 62-9.
108. Cuzick J, Stewart H, Rutqvist LE et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12: 447-53.
109. Borge N, Fosså SD, Stenwig AE. Metastatic testicular cancer and extragonadal germ cell tumor presenting with neurological symptoms. J Neurooncol 1990; 8: 145-8.
110. Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid neoplasms: Part I. J Surg Oncol 1995; 60: 137-46.
111. Spratt JS, Meyer JS, Spratt JA. Rates of growth of human solid neoplasms: Part II. J Surg Oncol 1996; 61: 68-83.
112. Oeser H v. Krebsbekämpfung: Hoffnung und Realität. Stuttgart: Georg Thieme Verlag; 1974.
113. Salmon SE, Smith BA. Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma. J Clin Invest 1970; 49: 1114-21.
114. Einhorn LH, Donohue J. Cis-diamminedichloroplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Int Med 1977; 87: 293-8.
115. Braun S, Pantel K, Muller P et al. Cytokeratin-positive cells in the bone marrow and survival patients with stage I, II, or III breast cancer. N Engl J Med 2000; 342: 525-33.
116. Hutchison GB, Shapiro S. Lead time gained by diagnostic screening for breast cancer. J Nat Cancer Inst 1968; 41: 665-81.
117. Boag JW. Maximum likelihood estimates of the proportion of patients cured by cancer therapy. J Roy Stat Soc 1949; 11: 15-53.
118. Michels P, Mirra J. Attacking the doubling time defense in breast cancer cases. Medical Trial Technique Quarterly 1981; 28: 301-321.
119. Parver CP. Defence of delayed diagnosis and treatment of breast cancer. Medical Trial Technique Quarterly 1983; 30: 34-63.
120. Friberg S. 5-year cure rate: Yet another myth. J Surg Oncol 1997; 65: 73-5.
121. Welch HG, Schwarte LM, Woloshin S. Are increasing 5-year survival rates evidence of success against cancer? JAMA 2000; 283: 2975-8.
122. Haybittle JL. Curability of breast cancer. Br Med Bull 1990; 47: 319-23.
123. Friberg S. Critical Analysis of Clinical Trials. In: Donegan WL, Spratt JS (eds.), Cancer of the Breast. Philadelphia: Saunders; 1998.
124. Spratt J. Realities of breast cancer control, public expectations, and law. Surg Oncol Clin North Am 1994; 3: 25-34.
125. Kem KA. The anatomy of surgical malpractice claims. Bull Am Coll Surg 1995; 80: 34-9.
126. Bailar III JC and Smith EM. Progress against cancer? N Engl J Med 1986; 314: 1226-32.
127. Bailar III JC, and Gomik HL. Cancer undefeated. N Engl J Med 1997; 336: 1569-74.
128. McKinnon NE. Cancer of the breast: the invalid evidence for faith in early treatment. Canad J Publ Health 1951; 42: 218-23.
129. Wright O, Mueller CB. Screening mammography and public health policy: the need for perspective. Lancet 1995; 346: 29-32.
130. Gotzsche PC and Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000; 355: 129-34.
131. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States. Cancer 1999; 86: 1867-76.
132. Eddy DM. Screening for lung cancer. Ann Int Med 1989; 111: 232-7.
133. Spratt JS and Spratt SW. Medical and legal implications of screening and follow-up procedures for breast cancer. Cancer 1990; 66: 1351-62.
134. McNichols D, Segura J, DeWeerd J. Renal cell carcinoma: Long-term survival and late recurrence. J Virol 1981; 126: 17-23.
135. Mueller CB: Stage II breast cancer is not simply a late stage I. Surgery 1988; 104: 631-8.